NILANJAN GAJARE: Open Payments
NPI 1972616191 · KALAMAZOO, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,263 in 169 payments from 12 companies in 2025. Trend: 2023 $3,725 · 2024 $3,662 · 2025 $4,263
Food & beverage: $4,051Education: $211
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $741 |
| Neurocrine BioSciences, Inc. | 26 | $580 |
| Teva Pharmaceuticals USA, Inc. | 19 | $569 |
| Alkermes, Inc. | 27 | $556 |
| E.R. Squibb & Sons, L.L.C. | 24 | $540 |
| Otsuka America Pharmaceutical, Inc. | 20 | $411 |
| Vanda Pharmaceuticals Inc. | 16 | $307 |
| Axsome Therapeutics, Inc. | 5 | $276 |
| Supernus Pharmaceuticals, Inc. | 7 | $119 |
| Lundbeck LLC | 4 | $110 |
Products named: CAPLYTA, INGREZZA, ARISTADA, COBENFY, FANAPT, REXULTI, AUSTEDO XR, Auvelity.
Industry payments across MI — which companies pay providers there.
